Global Business Report interviews Ymmunobio CEO Peter Schiemann

Check out the latest GBR Connect Series interview with our CEO and Co-Founder Peter Schiemann, where he talks about the latest Ymmunobio Developments and the key focus areas for 2024 to establish a positive proof of concept with our ADC candidate YB800 targeting a new receptor in GI Cancers.

You can access the full interview here: Global Business Reports - Peter Schiemann (gbreports.com)